Jose Roberto Gonzalez Sr. Suspended Through 2030 After Albuterol, Testosterone Positives

Trainer Jose Roberto Gonzalez Sr. will be ineligible to participate in racing activities through July 2, 2030 after regulators added a 36-month suspension to an earlier 18-month penalty tied to out-of-competition drug positives. The case centers on two Southwest-based runners tested at Albuquerque Downs and represents a high-profile enforcement action that underlines the sport’s ongoing attention to medication control.

The adjudication traces to a July 23, 2025 hair sample from Discovery N Sight that detected albuterol, which prompted the initial 18-month suspension that became effective Jan. 3, 2026 and included a $12,500 fine. Subsequent samples from Ol’ McClintock revealed albuterol in hair and testosterone in blood. Gonzalez admitted to the violations. The new measures add a $25,000 fine and a 36-month suspension that will begin July 2, 2027 and run to July 2, 2030. Taken together, Gonzalez faces $37,500 in fines and a continuous period of ineligibility that stretches from Jan. 3, 2026 through July 2, 2030 once the penalties are applied sequentially.

Beyond the trainer’s ban, the implicated horses face periods of ineligibility and must test clear before returning to training or competition. Discovery N Sight and Ol’ McClintock are effectively removed from the racing program until regulatory conditions for reinstatement are satisfied, a prospect that will affect owner plans, entry options at regional meets, and stable revenue tied to purses and stud value.

From a performance-analysis perspective, the positives for albuterol and testosterone carry different technical and public-relations weights. Albuterol is commonly used for respiratory conditions but is prohibited out-of-competition because it can mask underlying issues or provide an unfair advantage. A positive for testosterone is more acute in its implications as a performance-enhancing hormone and typically triggers stiffer sanctions and reputational damage. For trainers such as Gonzalez, admissions of wrongdoing crystallize the case and remove the ambiguity of contested defenses, while also prompting stewards and regulators to signal deterrence.

Industry trends make this case significant beyond one stable. Enforcement of out-of-competition testing has increased in many jurisdictions, and high-profile suspensions ripple through ownership groups, jockey bookings, and betting pools. Local racing circuits that rely on trained horses from established barns will feel the short-term disruption in entries and the longer-term reputational impact if bettors lose confidence in medication controls.

For fans and participants, the immediate takeaway is that two named horses are sidelined pending clear tests and that Jose Roberto Gonzalez Sr. will be barred from the sport for the better part of a decade when fines and staggered suspensions are combined. The case will be watched as a marker of how aggressively regulators pursue medication violations and as a test of how stables, owners, and racing offices manage horse placement and integrity in the seasons ahead.